Key result
Hodgkin lymphoma treatment with radiotherapy and chemotherapy is associated with a two- to fourfold increased risk of second malignant neoplasms and cardiovascular disease vs the general population.
Why the study?
What are the long-term risks of second malignancies and cardiovascular diseases in survivors of Hodgkin lymphoma?
What are the long-term risks of second malignancies and cardiovascular diseases in survivors of Hodgkin lymphoma?
Effect estimate: RR 2-4
Survivors of Hodgkin lymphoma face significantly elevated long-term risks of second malignancies and cardiovascular diseases, necessitating lifelong risk-based screening and preventive strategies.
No takes yet. Share an insight, caveat, or question.
Elevated risks warrant clinical awareness in Hodgkin lymphoma survivors; leaves open optimal screening protocols for prospective trials.
Leeuwen et al. (2016) conducted a review in Hodgkin lymphoma. Radiotherapy and chemotherapy vs. General population was evaluated on Second malignant neoplasms and cardiovascular disease (RR 2-4). Hodgkin lymphoma treatment with radiotherapy and chemotherapy is associated with a two- to fourfold increased risk of second malignant neoplasms and cardiovascular disease vs the general population.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: